The impact of EGFR-TKIs treatment on ground-glass opacity-featured lung adenocarcinama.

purposeThe objective of this study was to comprehensively assess the radiological and pathological impacts of Epidermal Growth Factor Receptor - Tyrosine Kinase Inhibitors (EGFR - TKIs) on ground - glass opacity (GGO) - featured lung adenocarcinoma. This evaluation aimed to provide valuable insights into the efficacy of EGFR - TKIs treatment for such tumors. CASE PRESENTATION: We present two cases of patients with multiple ground - glass opacities (mGGOs) and lung adenocarcinoma bearing primary EGFR mutations. In both cases, the patients underwent radical resection of the main lesions and subsequently received EGFR - TKIs treatment. The mGGOs in these patients demonstrated a sensitive response to the targeted therapy. Specifically, in Case 1, after 1 month of targeted treatment with gefitinib, the left upper lobe GGO lesion was partially absorbed, and it was completely absorbed after 3 months. In Case 2, 1 month after starting gefitinib treatment, the left upper lobe GGO lesion showed partial absorption.

conclusionThis study reports a potentially effective postoperative treatment strategy for mGGOs. The EGFR - TKI therapy appears to be beneficial for GGO - featured lung adenocarcinoma patients. However, further research is required to determine the optimal timing and approach for maximizing the therapeutic effect. Based on our findings, EGFR - TKI therapy can be considered as a viable treatment option for eligible patients.